FI104408B - Menetelmä kaksifaasisten vapautusformulaatioiden valmistamiseksi lipofiilisiä lääkkeitä varten - Google Patents

Menetelmä kaksifaasisten vapautusformulaatioiden valmistamiseksi lipofiilisiä lääkkeitä varten Download PDF

Info

Publication number
FI104408B
FI104408B FI931745A FI931745A FI104408B FI 104408 B FI104408 B FI 104408B FI 931745 A FI931745 A FI 931745A FI 931745 A FI931745 A FI 931745A FI 104408 B FI104408 B FI 104408B
Authority
FI
Finland
Prior art keywords
sustained release
pharmaceutically active
fatty acid
att
förfarande enligt
Prior art date
Application number
FI931745A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI931745A (fi
FI931745A0 (fi
Inventor
Stephen George Barnwell
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of FI931745A publication Critical patent/FI931745A/fi
Publication of FI931745A0 publication Critical patent/FI931745A0/fi
Application granted granted Critical
Publication of FI104408B publication Critical patent/FI104408B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Laminated Bodies (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
FI931745A 1990-10-19 1993-04-16 Menetelmä kaksifaasisten vapautusformulaatioiden valmistamiseksi lipofiilisiä lääkkeitä varten FI104408B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909022788A GB9022788D0 (en) 1990-10-19 1990-10-19 Pharmaceutical formulations
GB9022788 1990-10-19
GB9101824 1991-10-18
PCT/GB1991/001824 WO1992006680A1 (en) 1990-10-19 1991-10-18 Biphasic release formulations for lipophilic drugs

Publications (3)

Publication Number Publication Date
FI931745A FI931745A (fi) 1993-04-16
FI931745A0 FI931745A0 (fi) 1993-04-16
FI104408B true FI104408B (fi) 2000-01-31

Family

ID=10684032

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931745A FI104408B (fi) 1990-10-19 1993-04-16 Menetelmä kaksifaasisten vapautusformulaatioiden valmistamiseksi lipofiilisiä lääkkeitä varten

Country Status (21)

Country Link
US (1) US5391377A (hu)
EP (1) EP0553178B1 (hu)
JP (1) JP3276368B2 (hu)
KR (1) KR100188642B1 (hu)
AT (1) ATE122881T1 (hu)
AU (1) AU656924B2 (hu)
BG (1) BG61383B1 (hu)
CA (1) CA2093206C (hu)
CZ (1) CZ282822B6 (hu)
DE (1) DE69110052T2 (hu)
DK (1) DK0553178T3 (hu)
ES (1) ES2073177T3 (hu)
FI (1) FI104408B (hu)
GB (1) GB9022788D0 (hu)
HK (1) HK85296A (hu)
HU (2) HUT64215A (hu)
NO (1) NO305505B1 (hu)
RO (1) RO114739B1 (hu)
RU (1) RU2121344C1 (hu)
SK (1) SK279845B6 (hu)
WO (1) WO1992006680A1 (hu)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
GB9325445D0 (en) * 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
DE4443175A1 (de) * 1994-12-05 1996-06-13 Jenapharm Gmbh Neue pulsatile Arzneiform
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
JPH10513200A (ja) * 1995-02-06 1998-12-15 ナノシステムズ エルエルシー 可消化オイル又は脂肪酸中の微粒子分散物である化合物の製剤
EP0831870A4 (en) * 1995-06-07 1998-09-16 Avmax Inc USE OF ESSENTIAL OILS TO INCREASE THE BIOAVAILABILITY OF ORAL PHARMACEUTICAL COMPOUNDS
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6024980A (en) * 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
AU695734B2 (en) 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20030008919A1 (en) * 1999-06-03 2003-01-09 Jean-Baptiste Roullet Use of retinoids to treat high blood pressure and other cardiovascular disease
JP2002500190A (ja) 1998-01-08 2002-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 海洋海綿から誘導されるキネシンモーターモジュレーター
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
PL348193A1 (en) 1998-12-11 2002-05-06 Pharmasolutions Self-emulsifying compositions for drugs poorly soluble in water
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US20020132001A1 (en) * 2000-05-11 2002-09-19 Garthwaite Susan M. Aldosterone antagonist composition for release during aldosterone acrophase
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
CA2480826C (fr) * 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040077621A1 (en) * 2002-08-08 2004-04-22 Academia Sinica Antioxidants
EP1594512A4 (en) * 2003-02-11 2007-07-11 Kemia Inc COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
AU2005204391A1 (en) * 2004-01-14 2005-07-28 Lavipharm Laboratories, Inc. Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid
WO2005077331A1 (en) * 2004-02-11 2005-08-25 Athpharma Limited Chronotherapeutic compositions and methods of their use
US8741635B2 (en) 2004-05-12 2014-06-03 The Walter And Eliza Hall Institute Of Medical Research Method of cell isolation
EP2371846B1 (en) 2005-03-10 2013-12-04 Ben Gurion University of the Negev Research and Development Authority Ltd. Voltage dependent anion channel (vdac1) compositions and methods of use thereof for regulating apoptosis
US8648045B2 (en) 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
EP2269623A1 (en) 2005-04-29 2011-01-05 The Regents of The University of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2006135985A1 (en) 2005-06-24 2006-12-28 The Walter And Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
CN101426536A (zh) 2006-01-20 2009-05-06 妇女儿童健康研究院公司 治疗、预防和诊断骨病变的方法
EP2004680B1 (en) * 2006-04-06 2017-06-21 Ben-Gurion University Of The Negev N-terminal vdac variants and uses thereof
WO2007123153A1 (ja) * 2006-04-19 2007-11-01 Ono Pharmaceutical Co., Ltd. 経口投与用カプセル
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
WO2008015959A1 (fr) * 2006-08-01 2008-02-07 Otsuka Pharmaceutical Co., Ltd. Composition pharmaceutique permettant une meilleure absorption d'une substance pharmacologiquement active
CA2667925A1 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica N.V. Dry granulated pharmaceutical compositions and methods for producing same
AU2008279550B2 (en) * 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
SI2185198T1 (sl) 2007-08-02 2015-04-30 Gilead Biologics, Inc. Inhibitorji LOX in LOXL2 ter njihova uporaba
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2682400B1 (en) * 2007-08-28 2017-09-20 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US9149481B2 (en) * 2007-10-03 2015-10-06 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
US8715722B2 (en) * 2008-05-12 2014-05-06 Capsugel Belgium Nv Capsule with air-vents
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
CN102711809B (zh) 2009-08-17 2015-09-30 特雷康制药公司 使用抗-内皮因子抗体和抗-vegf剂联合治疗癌症
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
ES2363965B1 (es) * 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US9249189B2 (en) 2010-01-18 2016-02-02 Albany Medical College Alpha-fetoprotein “ring and tail” peptides
KR101930179B1 (ko) 2010-08-27 2018-12-17 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
BR112013009196A2 (pt) 2010-10-15 2020-08-25 The Trustees Of Columbia University In The City Of New York usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
AU2012249301A1 (en) 2011-04-29 2013-11-21 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
CA2850187C (en) * 2011-09-29 2021-12-07 Plx Pharma Inc. Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
CN107184974A (zh) 2012-02-29 2017-09-22 吉利德生物制剂公司 抗基质金属蛋白酶9的抗体
BR112014021477A2 (pt) 2012-02-29 2018-06-12 Gilead Sciences Inc anticorpos para metaloproteinase de matriz 9
CN104203263A (zh) 2012-03-01 2014-12-10 耶达研究与发展有限公司 利用HSP60衍生肽再生胰岛β细胞
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
JP2015524397A (ja) 2012-07-20 2015-08-24 ラトローブ ユニヴァーシティ 診断及び処置の方法
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
CA2903869A1 (en) 2013-03-14 2014-09-25 Uab Research Foundation Apolipoprotein e dosing regimen for treating atherosclerosis
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
JP2016519651A (ja) 2013-03-15 2016-07-07 アンジェリカ セラピューティックス，インク． 改質された毒素
WO2015011711A1 (en) 2013-07-25 2015-01-29 The National Institute for Biotechnology in the Negev Ltd. Short peptides derived from vdac1, compositions and methods of use thereof
US9873724B2 (en) 2013-12-20 2018-01-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pro-angiogenic peptides and peptide conjugates
EP3110847A1 (en) 2014-02-27 2017-01-04 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9 and methods of use thereof
BR112016028750A2 (pt) 2014-06-11 2017-11-14 Gilead Sciences Inc ?métodos para tratar, prevenir, ou melhorar pelo menos um sintoma associado e para diagnosticar e monitorar insuficiência cardíaca ou fibrilação atrial, inibidor da lisil oxidase ativa ou proteína lisil tipo oxidase, e, composição?
US10793614B2 (en) 2014-07-17 2020-10-06 Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. Antagonists of fish reproduction
US10155790B2 (en) 2014-07-17 2018-12-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antagonists of neurokinin B in fish reproduction
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
US10617738B2 (en) 2015-10-27 2020-04-14 The University Of Queensland Mammalian EphA4 polypeptide derivatives lacking one or more N-glycosylation sites and method of use thereof
WO2017083700A1 (en) 2015-11-13 2017-05-18 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
US20170174788A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
WO2017177179A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
US11154591B2 (en) 2016-10-14 2021-10-26 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
JP2020506923A (ja) 2017-01-30 2020-03-05 ハドソン インスティテュート オブ メディカル リサーチ 治療方法
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
KR102344616B1 (ko) 2017-05-30 2021-12-31 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 항-더블코르틴-유사 키나제 1 항체 및 사용 방법
JP7054418B2 (ja) 2017-11-08 2022-04-13 ビオンテック ユーエス インコーポレイテッド Ｔ細胞を製造する組成物及び方法
JP2022536684A (ja) 2019-06-11 2022-08-18 マイエロイド・セラピューティクス，インコーポレーテッド マクロファージ特異的エンゲージャー組成物およびその使用方法
CA3141084A1 (en) 2019-06-12 2020-12-17 Vikram JUNEJA Neoantigen compositions and uses thereof
MX2022011743A (es) * 2020-03-26 2022-12-08 Plx Opco Inc Portadores farmaceuticos con capacidad de reconstitucion dependiente del ph y metodos para elaborar y usar los mismos.
EP4196135A4 (en) 2020-08-13 2024-08-21 Biontech Us Inc COMPOSITIONS AND METHODS FOR PRODUCING T CELLS
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1600639A (en) * 1978-05-23 1981-10-21 Kali Chemie Pharma Gmbh Medicament preparation having resorption properties and method of producing the same
US4916230A (en) * 1984-07-02 1990-04-10 Merck & Co., Inc. Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
IT1200178B (it) * 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
US5229422A (en) * 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
EP0351897A3 (en) * 1988-06-17 1990-03-21 The Procter & Gamble Company Skin penetration system for salts of amine-functional drugs
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB8909022D0 (en) * 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
HK85296A (en) 1996-05-24
FI931745A (fi) 1993-04-16
ES2073177T3 (es) 1995-08-01
KR930701989A (ko) 1993-09-08
NO931410D0 (no) 1993-04-16
SK279845B6 (sk) 1999-04-13
CA2093206A1 (en) 1992-04-20
RU2121344C1 (ru) 1998-11-10
AU656924B2 (en) 1995-02-23
DE69110052T2 (de) 1995-10-05
GB9022788D0 (en) 1990-12-05
HUT64215A (en) 1993-12-28
JPH06502143A (ja) 1994-03-10
JP3276368B2 (ja) 2002-04-22
ATE122881T1 (de) 1995-06-15
EP0553178B1 (en) 1995-05-24
WO1992006680A1 (en) 1992-04-30
CA2093206C (en) 2002-01-29
CZ64193A3 (en) 1994-01-19
EP0553178A1 (en) 1993-08-04
NO931410L (no) 1993-04-16
FI931745A0 (fi) 1993-04-16
BG61383B1 (en) 1997-07-31
CZ282822B6 (cs) 1997-10-15
KR100188642B1 (ko) 1999-06-01
SK36393A3 (en) 1993-07-07
NO305505B1 (no) 1999-06-14
DE69110052D1 (de) 1995-06-29
HU9301121D0 (en) 1993-07-28
HU211617A9 (en) 1995-12-28
BG97644A (bg) 1994-04-29
DK0553178T3 (da) 1995-07-24
RO114739B1 (ro) 1999-07-30
AU8731591A (en) 1992-05-20
US5391377A (en) 1995-02-21

Similar Documents

Publication Publication Date Title
FI104408B (fi) Menetelmä kaksifaasisten vapautusformulaatioiden valmistamiseksi lipofiilisiä lääkkeitä varten
US10668038B2 (en) Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
JP6835664B2 (ja) 脂肪酸油混合物の被覆型カプセル剤および錠剤
Perlman et al. Development of a self-emulsifying formulation that reduces the food effect for torcetrapib
US20210059949A1 (en) Modified release composition comprising a cannabinoid
US6596308B2 (en) Controlled release pharmaceutical composition
JP6896019B2 (ja) 脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法
JP5583119B2 (ja) インドリノン誘導体の即時放出のための医薬投薬形態
JP2013508348A5 (hu)
CA2982162C (en) Self-emulsifying formulations of dim-related indoles
JP6276756B2 (ja) １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤
US20110033529A1 (en) Oral pharmaceutical paricalcitol formulations
BRPI0008228B1 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
WO2009069139A1 (en) Dosage form providing an ibuprofen-containing liquid fill
WO2021163023A1 (en) Stable formulations of dronabinol
HRP980378A2 (en) Encapsulated solution dosage forms of sertraline
TW202128150A (zh) ３＇—［（２ｚ）—［１—（３，４—二甲基苯基）—１，５—二氫—３—甲基—５—側氧基—４ｈ—吡唑—４—亞基］肼基］—２＇—羥基—［１，１＇—聯苯基］—３—甲酸及其鹽配製物
WO2012066347A1 (en) Oil based formulations
AU2922800A (en) Pharmaceutical compositions for oral administration comprising a benzamide and at least an absorption promoter
KR20100022626A (ko) 나노입자 형성을 이용하는 리세드로네이트 경질캡슐